|
1
|
Dominique Guyader (2002)
|
Multicenter trail
|
RCT
|
NA
|
Double-blind
|
1 d
|
N
|
palcebo
|
5
|
55.6 ± 10.1
|
3/2
|
139.0 ± 3.2
|
|
VPA-985 25 mg
|
4
|
58.5 ± 9.5
|
3/1
|
140.5 ± 2.1
|
|
VPA-985 50 mg
|
5
|
59.4 ± 6.0
|
5/0
|
135.7 ± 5.2
|
|
VPA-985 100 mg
|
4
|
61.2 ± 8.0
|
3/1
|
131.0 ± 6.0
|
|
VPA-985 200 mg
|
4
|
62.8 ± 5.8
|
3/1
|
139.0 ± 3.0
|
|
VPA-985 300 mg
|
5
|
49.0 ± 2.9
|
4/1
|
136.0 ± 2.1
|
|
2
|
Alexanderl. Gerbes (2003)
|
Multicenter trail
|
RCT
|
Computerized randomization
|
Double-blind
|
7 d
|
NA
|
palcebo
|
20
|
58 ± 2
|
15/5
|
127.3 ± 3.0
|
|
VPA-985 100 mg/d
|
22
|
54 ± 3
|
17/5
|
128.3 ± 4.1
|
|
VPA-985 200 mg/d
|
18
|
56 ± 3
|
14/4
|
126.4 ± 4.4
|
|
3
|
Florence Wong (2003)
|
Multicenter trail
|
RCT
|
Computerized randomization
|
NA
|
7 d
|
Y
|
palcebo
|
8
|
NA
|
NA
|
127 ± 1
|
|
VPA-985 50 mg/d
|
8
|
126 ± 1
|
|
VPA-985 250 mg/d
|
10
|
122 ± 2
|
|
VPA-985 500 mg/d
|
7
|
125 ± 1
|
|
4
|
PJ THULUVAT H (2006)
|
USA
|
RCT
|
NA
|
Double-blind
|
1 d
|
Y
|
palcebo
|
6
|
50.5 ± 7.6
|
4/2
|
136 ± 2
|
|
RWJ-351647 1 mg
|
6
|
56.5 ± 5.2
|
4/2
|
136 ± 5
|
|
RWJ-351647 2 mg
|
6
|
51.5 ± 7
|
5/1
|
137 ± 2
|
|
RWJ-351647 5 mg
|
6
|
48.3 ± 1.2
|
5/1
|
136 ± 3
|
|
5
|
Pere Gines (2008)
|
Multicenter trail
|
RCT
|
Computerized randomization
|
Double-blind
|
14 d
|
Y
|
palcebo
|
28
|
55 ± 10
|
22/6
|
NA
|
|
Satavaptan 5 mg/d
|
28
|
57 ± 8
|
16/12
|
|
Satavaptan 12.5 mg/d
|
26
|
56 ± 9
|
19/7
|
|
Satavaptan 25 mg/d
|
28
|
59 ± 10
|
20/8
|
|
6
|
Florence Wong (2010)
|
Multicenter trail
|
RCT
|
Computerized randomization
|
Double-blind
|
12 weeks
|
Y
|
palcebo
|
36
|
60 ± 9
|
26/10
|
136 ± 4
|
|
Satavaptan 5 mg/d
|
39
|
59 ± 9
|
32/7
|
133 ± 6
|
|
Satavaptan 12.5 mg/d
|
36
|
59 ± 9
|
28/8
|
135 ± 5
|
|
Satavaptan 25 mg/d
|
40
|
60 ± 11
|
29/11
|
134 ± 5
|
|
7
|
Pere Gines (2010)
|
Multicenter trail
|
RCT
|
Computerized randomization
|
Double-blind
|
14 d
|
Y
|
palcebo
|
35
|
58 ± 9
|
22⁄13
|
137 ± 3
|
|
Satavaptan 5 mg/d
|
40
|
58 ± 9
|
30⁄10
|
137 ± 3
|
|
Satavaptan 12.5 mg/d
|
35
|
57 ± 8
|
26⁄9
|
136 ± 4
|
|
Satavaptan 25 mg/d
|
38
|
55 ± 9
|
25⁄13
|
136 ± 2
|
|
8
|
Andres Cardenas (2012)
|
USA
|
RCT
|
Stratified random
|
Double-blind
|
30 d
|
Y
|
Placebo
|
57
|
55 ± 9
|
38/19
|
NA
|
|
Tolvaptan 15-60 mg/d
|
63
|
52 ± 8
|
50/13
|
|
9a
|
Florence Wong (2012)a
|
Multicenter trail
|
RCT
|
Stratified random
|
Double-blind
|
52 weeks
|
Y
|
placebo
|
230
|
56.4 ± 9.2
|
168/62
|
NA
|
|
Satavaptan 5 or 10 mg/d
|
232
|
56.6 ± 10.2
|
158/74
|
|
9b
|
Florence Wong (2012)b
|
Multicenter trail
|
RCT
|
Stratified random
|
Double-blind
|
52 weeks
|
Y
|
placebo
|
168
|
57.0 ± 9.8
|
113/55
|
NA
|
|
Satavaptan 5 or 10 mg/d
|
328
|
58.9 ± 10.0
|
237/91
|
|
9c
|
Florence Wong (2012)c
|
Multicenter trail
|
RCT
|
Stratified random
|
Double-blind
|
52 weeks
|
N
|
placebo
|
80
|
56.2 ± 9.9
|
50/30
|
NA
|
|
Satavaptan 5 or 10 mg/d
|
160
|
56.4 ± 9.6
|
108/52
|
|
10
|
Isao Sakaida (2014)
|
Japan
|
RCT
|
NA
|
Double-blind
|
7 d
|
Y
|
placebo
|
80
|
NA
|
49/31
|
135.7 ± 4.1
|
|
tolvaptan 7.5 mg/d
|
82
|
52/30
|
135.3 ± 4.5
|
|
11
|
Kiwamu Okita (2014)
|
Japan
|
RCT
|
NA
|
Double-blind
|
7 d
|
Y
|
placebo
|
26
|
64 ± 10
|
17/9
|
NA
|
|
tolvaptan 7.5 mg/d
|
25
|
65 ± 9
|
18/7
|
|
tolvaptan 15 mg/d
|
25
|
65 ± 10
|
21/4
|
|
tolvaptan 30 mg/d
|
25
|
63 ± 10
|
15/10
|
|
12
|
Pere Gines (2007)
|
Multicenter trail
|
RCT
|
NA
|
Single-blind
|
52 weeks
|
Y
|
placebo
|
47
|
NA
|
NA
|
132.5
|
|
satavaptan 5 mg/d-50 mg/d
|
26
|
131.7
|
|
13
|
Pere Gines (2008)’
|
Multicenter trail
|
RCT
|
NA
|
Single-blind
|
52 weeks
|
Y
|
placebo
|
92
|
NA
|
NA
|
NA
|
|
satavaptan 5 mg/d-50 mg/d
|
47
|
|
14
|
Florence Wong (2009)
|
Multicenter trail
|
RCT
|
NA
|
Single-blind
|
52 weeks
|
Y
|
placebo
|
48
|
NA
|
NA
|
NA
|
|
satavaptan 5 mg/d-50 mg/d
|
186
|
